In a non-randomized clinical trial, Dexmedetomidine injection minimized labor pain and expedited the mean duration of first stage of labor without triggering any complications for the mother or the newborn. The goal of Abasali Delavari et al. was to assess how Dexmedetomidine intravenous infusion affected the treatment of labor pain in primipara term pregnant women.

Primipara term pregnant ladies were incorporated. After the active phase of labor, Dexmedetomidine was administered to the intervention group in accordance with the protocol and continued until phase 2 of labor. The control group didn't get any pain-relieving measures. Sedation score, pain severity, vital signs, Apgar scores, and fetal heart rate were assessed for patients in both groups.

Primary maternal hemodynamics, primary fetal heart rate, and mean Apgar scores at 1 and 5 minutes did not differ substantially between both the groups. The mean fetal heart rate in various stages did not differ profoundly between both the groups. The mean systolic and diastolic blood pressures in the intervention group were considerably lower following the administration of drug but remained within the normal range, according to intragroup analyses.

The intervention group's active phase of labor was noticeably shorter than that of the control group. Following Dexmedetomidine use, the mean Visual Analogue Scale (VAS) score dramatically dropped from 9.25 at baseline to 4.61 after medication administration, 3.88 throughout labor, and 1.88 after placental ejection, as shown in Figure 1:

Dexmedetomidine treatment resulted in a considerable rise in the mean Ramsay Sedation Scale score, which elevated from 1.00 at baseline to 2.05 after drug use, 2.22 throughout labor, and 2.05 following placental ejection. According to this study's findings, Dexmedetomidine should be used to treat labor pain while carefully monitoring both the fetus and mother.